Related Experiment Videos
New antileukemic agents
Elpis Mantadakis1, Maria Kalmanti
1Pediatric Hematology/Oncology Clinic, University Hospital of Heraklion, Heraklion, Crete, Greece.
Abstract:
Despite the tremendous progress in the treatment of childhood leukemias over the last 50 years, certain subgroups of children continue to have poor prognosis. Hence, there is a need for development of new antileukemic agents. In this review, the authors describe results of clinical trials of several new antileukemic compounds with different mechanisms of action (signal transduction inhibitors, nucleoside analogs, DNA hypomethylators, angiogenesis inhibitors, and monoclonal antibodies). Although most of these compounds are not used in pediatric leukemias, the concepts surrounding their clinical development are important to all pediatric hematologists/oncologists.
Insights
New antileukemic agents are needed for childhood leukemia subgroups with poor prognosis. This review covers novel compounds and their clinical development concepts, crucial for pediatric hematologists/oncologists.
Area of Science:
- Pediatric Oncology
- Hematology
- Pharmacology
Background:
- Childhood leukemias have seen treatment advances, but some patient groups still face poor outcomes.
- There is a critical need for novel therapeutic strategies and antileukemic agents in pediatric oncology.
Purpose of the Study:
- To review the clinical trial results of emerging antileukemic compounds.
- To discuss the clinical development concepts of new agents for pediatric hematologists/oncologists.
Main Methods:
- Literature review of clinical trials involving new antileukemic compounds.
- Analysis of compounds with diverse mechanisms of action, including signal transduction inhibitors, nucleoside analogs, DNA hypomethylators, angiogenesis inhibitors, and monoclonal antibodies.
Main Results:
- Several new antileukemic compounds targeting different pathways have shown promise in clinical trials.
- While not all compounds are currently used in pediatric leukemias, their development principles are relevant.
Conclusions:
- The development of novel antileukemic agents is essential for improving outcomes in pediatric leukemia subgroups with poor prognosis.
- Understanding the clinical development of these new agents is vital for advancing pediatric hematology/oncology practice.